Latest From Isto Biologics
Global sales of orthobiologics for musculoskeletal soft tissue replacement and regeneration are predicted to hit $1.4bn by 2021, driven largely by rising numbers of sports injuries requiring treatment, but also by a higher prevalence of osteoarthritis and a need for innovative treatments for musculoskeletal repair. This article offers an in-depth look at the orthobiologics market landscape for cartilage, meniscus and ligament/tendon replacement and regeneration, as well as insight from an orthopedic surgeon. It also analyzes key players in these markets and highlights emerging trends and the greatest barriers for wider adoption of products.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.
The US market for orthopedic extremities and soft-tissue repair products will grow by $2.2 billion over the next five years, according to a global market report from Medtech Insight. Major factors contributing to the strong growth of this market include: the expanding elderly demographic, an increase in the number of active adults who are prone to physical injuries, and improvements in biological material and implants that reduce complications and improve quality of life.
CartiHeal's simple, cell-free construct may offer a potential solution to one of the greatest unsolved problems in musculoskeletal surgery – cartilage regeneration. An interview with Nir Altschuler, founder and CEO of the Israeli start-up.
- Gene Therapy, Cell Therapy
- Implantable Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Isto Technologies Inc.
- North America
- Parent & Subsidiaries
- Isto Biologics
- Senior Management
George Dunbar, Pres. & CEO
Mary Vonesh, CFO
Phillip Kuhn, Chief Commercial Officer
Davis Adkisson, PhD, CSO
- Contact Info
Phone: (314) 995-6049
1155 Olivette Executive Pkwy., Ste. 200
St. Louis, MO 63132
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.